About US
Contact us
-
Bristol Myers Squibb, awaiting Opdivo-Yervoy approval, trumpets 3-year lung cancer survival winJust days away from an FDA decision that could finally bring Bristol Myers Squibb’s Opdivo to previously untreated non-small cell lung cancer patients, the company’s Opdivo-Yervoy combo has put up po2020/5/8
-
J&J's Erleada extends lives by 14 months in nonmetastatic prostate cancerLast September, Johnson & Johnson said prostate cancer med Erleada had “barely missed” showing it could extend the lives of patients with nonmetastatic castration-resistant disease. But it’s now2020/5/7
-
AZ, Merck's Lynparza levels up in ovarian cancer, extending lives by 13 monthsWith competitor Zejula threatening to steal share after a key new approval, AstraZeneca and Merck’s Lynparza is taking things to the next level in BRCA-mutated ovarian cancer with evidence it can ext2020/5/7
-
Roche's Alecensa stays on top of Xalkori with long-term survival showingRoche made a splash at the American Society of Clinical Oncology (ASCO) annual meeting three years ago with data showing its Alecensa could top Pfizer’s Xalkori at keeping ALK-positive lung-cancerat2020/5/6
-
Merck's Keytruda thumped SeaGen's Adcetris in a head-to-head trial. How much does it matter?Merck’s Keytruda has taken on the standard of care in classical Hodgkin lymphoma and won. But with a closely watched combination making its way through the clinic,how long will the results be relevan2020/5/6
-
AstraZeneca, with a heavy focus on China, sees key meds outperform despite COVID-19When the novel coronavirus was first identified in China and put the entire country on high alert, there were concerns that the outbreak would hit AstraZeneca hard, given its high exposure to the eme2020/4/30
-
Merck grabs FDA green light for less-frequent Keytruda dosing regimenThat didn’t take long. Just days after resubmitting its application to the FDA, Merck nabbed an approval Tuesday for a new, more convenientKeytruda dosing regimen The FDAgreen lightclearedthe immuno-2020/4/30
-
Merck, with a heavy presence in physician-administered drugs, predicts a $2.1B sales hit from COVID-19Whiledrugmakersacross the industry deal withtheir respectiveCOVID-19challenges, Merck faces a unique set of circumstances because of its reliance on physician-administered drugs. Several companies ha2020/4/29
-
Novartis, already trialing hydroxychloroquine and Jakafi, plans COVID-19 testing for IlarisAnother existing drug is being pitted against COVID-19. This time, it’s Novartis’ immunology med Illaris. On Monday, Novartis said itplannedto studyIlaris (canakinumab) in a phase 3 trial to see if t2020/4/28
-
Gilead ratchets up its Truvada patent fight with U.S. in new breach-of-contract lawsuitGilead Sciences and federal authorities have been locked in a high-stakes fight over patents on an HIV prevention drug, and now Gilead has filed the latest salvo. In a new lawsuit, the Big Biotech cl2020/4/28